SGLT2 inhibitor is a new type of hypoglycemic agent, and various SGLT2 inhibitors can significantly reduce the left ventricle ejection fraction of patients in several large-scale recently finished and underway clinical studies, which is expected to reduce the mortality of heart failure patients. The gene discussed is SLC5A2; the disease is heart failure.